Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pathway Polygenic Risk Scores (pPRS) for the Analysis of Gene-environment Interaction.
Gauderman WJ, Fu Y, Queme B, Kawaguchi E, Wang Y, Morrison J, Brenner H, Chan A, Gruber SB, Keku T, Li L, Moreno V, Pellatt AJ, Peters U, Samadder NJ, Schmit SL, Ulrich CM, Um C, Wu A, Lewinger JP, Drew DA, Mi H. Gauderman WJ, et al. Among authors: moreno v. bioRxiv [Preprint]. 2024 Dec 19:2024.12.16.628610. doi: 10.1101/2024.12.16.628610. bioRxiv. 2024. PMID: 39763728 Free PMC article. Preprint.
Metabolomic Changes Associated With the Change in HVPG After DAAs Therapy in HCV Cirrhotic Patients.
Virseda-Berdices A, Martín-Escolano R, Berenguer J, González-García J, Brochado-Kith O, Rojo D, Díez C, Hontañon V, Pérez-Latorre L, Ibañez-Samaniego L, Llop-Herrera E, Olveira A, Fernández-Rodríguez A, Barbas C, Resino S, Jiménez-Sousa MÁ; ESCORIAL Study Group. Virseda-Berdices A, et al. Liver Int. 2025 Jan;45(1):e16204. doi: 10.1111/liv.16204. Liver Int. 2025. PMID: 39708286
Understanding the Preclinical Efficacy of Antibody-Drug Conjugates.
Díaz-Tejeiro C, López de Sá A, Poyatos-Racionero E, Ballestín P, Bartolomé J, Calvo E, Moreno V, Moris F, Pérez-Segura P, Gyorffy B, Pandiella A, Ocaña A. Díaz-Tejeiro C, et al. Among authors: moreno v. Int J Mol Sci. 2024 Nov 29;25(23):12875. doi: 10.3390/ijms252312875. Int J Mol Sci. 2024. PMID: 39684584 Free PMC article. Review.
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.
Luke JJ, Gelmon K, Siu LL, Moreno V, Desai J, Gomez-Roca CA, Carlino MS, Pachynski RK, Cosman R, Chu QS, Damian S, Curigliano G, Tam R, Wang X, Jeyamohan C, Wang L, Zhu L, Santucci-Pereira J, Greenawalt DM, Tabernero J. Luke JJ, et al. Among authors: moreno v. Clin Cancer Res. 2024 Dec 13. doi: 10.1158/1078-0432.CCR-24-0439. Online ahead of print. Clin Cancer Res. 2024. PMID: 39670852
1,204 results